All treatments
Treatment
Armisarte 25 mg/ml concentrate for solution for infusion clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Global, Randomized, Phase 3, Open-Label Study of REGN2810 (Anti-PD-1 Antibody) versus Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic PD-L1 + Non-Small Cell Lung Cancer
This study looks at a new drug (REGN2810) compared to standard chemotherapy for advanced non-small cell lung cancer. It aims to see if the new drug helps people live longer and stops cancer from growing, especially for those whose cancer has a specific protein called PD-L1.
For: Non-small Cell Lung CancerCzechia · Poland · Greece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab (Anti- PD-1 Antibody) and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
This study is testing new combinations of anti-cancer medicines for people with advanced non-small cell lung cancer. It aims to see if these new approaches can help people live longer and improve their quality of life, compared to standard treatments.
For: Non-small Cell Lung CancerFrance · Poland · Ireland